Preoperative radiotherapy in stage I/II endometrial adenocarcinoma

被引:6
作者
Maingon, P [1 ]
Horiot, JC [1 ]
Fraisse, J [1 ]
Salas, S [1 ]
Collin, F [1 ]
BoneLepinoy, MC [1 ]
Barillot, I [1 ]
Douvier, S [1 ]
Padeano, MM [1 ]
Cuisenier, J [1 ]
机构
[1] CHU DIJON,F-21000 DIJON,FRANCE
关键词
endometrial carcinoma; preoperative radiotherapy; brachytherapy; surgery; complication;
D O I
10.1016/0167-8140(96)01743-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
From 1972 to 1993, 170 patients received preoperative radiotherapy followed, 5-6 weeks later, by total extrafascial hysterectomy with bilateral salpingo-oophorectomy without lymphadenectomy. Eighty-three :patients with good prognostic factors (low grade tumour and no cervical involvement) received low dose rate utero vaginal brachytherapy alone before surgery (Group 1). Eighty-seven patients with poor prognostic factors (high grade tumors and/or cervical involvement) received external radiotherapy to 40 Gy and low dose rate brachytherapy before surgery (Group 2). A single vaginal failure was observed (0.6%). The overall pelvic failure rate was 2.3% (four patients) including two cases with pelvic recurrence and metastases. Three of the four pelvic failures occurred in Group 1. Using the 1971 FIGO clinical staging, 5-year disease-free survival was 82% in Stage Ia, 79% in Stage Ib, and 81% in Stage II (P = 0.36). Five-year disease-free survival was 86% in Grade 1, 76% in Grade 2, and 83% in Grade 3 (P = 0.20). Five-year overall survival was 83% in Stage Ia, 79% in Stage Ib, and 83% in Stage II (P = 0.78). Five-year overall survival was 88% in Grade 1, 77% in Grade 2, 83% in Grade 3 (P = 0.27). Complications were recorded with the French-Italian syllabus. Grade 2 complications occurred in 12 cases (7%), Grade 3 in five cases (3%). The lack of correlation between classical risk factors (stage, grade) and disease outcome suggests that preoperative radiotherapy strategies should be preferred when such factors can be identified before surgery.
引用
收藏
页码:201 / 208
页数:8
相关论文
共 37 条
[1]  
AALDERS J, 1980, OBSTET GYNECOL, V56, P419
[2]  
BEDWINEK J, 1984, CANCER, V54, P40, DOI 10.1002/1097-0142(19840701)54:1<40::AID-CNCR2820540111>3.0.CO
[3]  
2-T
[4]   PREOPERATIVE OR POSTOPERATIVE BRACHYTHERAPY FOR PATIENTS WITH ENDOMETRIAL CARCINOMA STAGE-I AND STAGE-II [J].
CALAIS, G ;
VITU, L ;
DESCAMPS, P ;
BODY, G ;
REYNAUDBOUGNOUX, A ;
LANSAC, J ;
BOUGNOUX, P ;
LEFLOCH, O .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (03) :523-527
[5]   A GLOSSARY FOR REPORTING COMPLICATIONS OF TREATMENT IN GYNECOLOGICAL CANCERS [J].
CHASSAGNE, D ;
SISMONDI, P ;
HORIOT, JC ;
SINISTRERO, G ;
BEY, P ;
ZOLA, P ;
PERNOT, M ;
GERBAULET, A ;
KUNKLER, I ;
MICHEL, G .
RADIOTHERAPY AND ONCOLOGY, 1993, 26 (03) :195-202
[6]  
CHEON HK, 1969, OBSTET GYNECOL, V34, P680
[7]  
CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO
[8]  
2-8
[9]   DOSE-VOLUME ANALYSIS AND THE PREVENTION OF RADIATION SEQUELAE IN CERVICAL-CANCER [J].
CROOK, JM ;
ESCHE, BA ;
CHAPLAIN, G ;
ISTURIZ, J ;
SENTENAC, I ;
HORIOT, JC .
RADIOTHERAPY AND ONCOLOGY, 1987, 8 (04) :321-332
[10]  
EIFEL PJ, 1983, CANCER, V52, P1026, DOI 10.1002/1097-0142(19830915)52:6<1026::AID-CNCR2820520617>3.0.CO